ALL
51
3
ADBE
61
11
NOV
55
-4
SWKS
51
-2
VMC
60
-2
FLR
56
-2
ADT
50
2
GILD
54
3
MMC
67
2
AMGN
31
-16
LEN
57
-4
DOV
69
2
AVY
54
-4
NWSA
63
-4
HSIC
60
-2
LB
60
4
VFC
50
-2
UPS
61
-3
ISRG
74
3
FFIV
69
2
ALL
51
3
ADBE
61
11
NOV
55
-4
SWKS
51
-2
VMC
60
-2
FLR
56
-2
ADT
50
2
GILD
54
3
MMC
67
2
AMGN
31
-16
LEN
57
-4
DOV
69
2
AVY
54
-4
NWSA
63
-4
HSIC
60
-2
LB
60
4
VFC
50
-2
UPS
61
-3
ISRG
74
3
FFIV
69
2
Financhill
Back

Takeda Pharmaceutical 10K Form

Sell
24

TAK
Takeda Pharmaceutical

Last Price:
13.59
Seasonality Move:
5.04%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TAK News And Ratings

See the #1 stock for the next 7 days that we like better than TAK

TAK Financial Statistics

Sales & Book Value

Annual Sales: $29.55B
Cash Flow: $1.28B
Price / Cash Flow: 12.44
Annual Sales: $15.29
Price / Book: 0.88

Profitability

EPS (TTM): 0.60440
Net Income (TTM): $1.93B
Gross Margin: $19.66B
Return on Equity: 4.01%
Return on Assets: 1.91%

Takeda Pharmaceutical Earnings Forecast

Key Takeda Pharmaceutical Financial Ratios

  • The Gross Profit Margin over the past 25 years for TAK is 66.54%.
  • The Selling, General & Administrative Expenses for TAK have been equal to 24.72% of Gross Profit Margin.
  • The Research & Development expenses have been 17.12% of Revenue.
  • The Interest Expense is 82.97% of Operating Income.
  • The Net Earning history of TAK is 3.38% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 15 years.

Takeda Pharmaceutical Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: TAK
CUSIP: 874060
Website: takeda.com

Debt

Debt-to-Equity Ratio: 0.73
Current Ratio: 1.28
Quick Ratio: 0.68

Price-to-Earnings

Trailing P/E Ratio: 42.55
Forward P/E Ratio: 0

TAK Technical Analysis vs Fundamental Analysis

Sell
24
Takeda Pharmaceutical (TAK) is a Sell

Is Takeda Pharmaceutical a Buy or a Sell?